Sitagliptin and the risk of hospitalization for heart failure: A population-based study

Kang Ling Wang; Chia Jen Liu; Tze Fan Chao; Chi Ming Huang; Cheng Hsueh Wu; Su Jung Chen; Chiu Mei Yeh; Tzeng Ji Chen; Shing Jong Lin; Chern En Chiang

doi:10.1016/j.ijcard.2014.09.038

Sitagliptin and the risk of hospitalization for heart failure: A population-based study

Kang Ling Wang, Chia Jen Liu, Tze Fan Chao, Chi Ming Huang, Cheng Hsueh Wu, Su Jung Chen, Chiu Mei Yeh, Tzeng Ji Chen, Shing Jong Lin^*, Chern En Chiang

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Abstract

Background Saxagliptin was associated with an increased risk of hospitalization for heart failure (HHF) in diabetic patients with high cardiovascular risk. This study assessed the risk of HHF during an exposure to sitagliptin in general diabetic patients.

Methods In Taiwan National Health Insurance research database, a study of the beneficiaries aged ≥ 45 years with diabetes treated with or without sitagliptin between March 2009 and July 2011 was conducted. Patients treated with sitagliptin were matched to patients never exposed to a dipeptidyl peptidase-4 (DPP-4) inhibitor by the propensity score methodology. The outcome measures were the first and the total number of HHF, and mortality for heart failure or all causes.

Results A total of 8288 matched pairs of patients were analyzed. During a median of 1.5 years, the first event of HHF occurred in 339 patients with sitagliptin and 275 patients never exposed to a DPP-4 inhibitor (hazard ratio: 1.21, 95% confidence interval: 1.04-1.42, P = 0.017); all-cause mortality was similar (hazard ratio: 0.87, 95% confidence interval: 0.74-1.03, P = 0.109). The risk for HHF was proportional to exposure (hazard ratio: 1.09, 95% confidence interval: 1.06-1.11, P < 0.001 for every 10% increase in adherence to sitagliptin). Overall, there were 935 events of HHF, in which the association between the number of HHF and the adherence to sitagliptin was linear. The greatest total number of HHF occurred in the patients with the highest adherence.

Conclusions The use of sitagliptin was associated with a higher risk of HHF but no excessive risk for mortality was observed.

Original language	English
Pages (from-to)	86-90
Number of pages	5
Journal	International Journal of Cardiology
Volume	177
Issue number	1
DOIs	https://doi.org/10.1016/j.ijcard.2014.09.038
State	Published - 15 Nov 2014

Keywords

Sitagliptin Heart failure Outcome research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ijcard.2014.09.038

Cite this

@article{4e48fccb88004ded92dc73dfd9319500,

title = "Sitagliptin and the risk of hospitalization for heart failure: A population-based study",

abstract = "Background Saxagliptin was associated with an increased risk of hospitalization for heart failure (HHF) in diabetic patients with high cardiovascular risk. This study assessed the risk of HHF during an exposure to sitagliptin in general diabetic patients.Methods In Taiwan National Health Insurance research database, a study of the beneficiaries aged ≥ 45 years with diabetes treated with or without sitagliptin between March 2009 and July 2011 was conducted. Patients treated with sitagliptin were matched to patients never exposed to a dipeptidyl peptidase-4 (DPP-4) inhibitor by the propensity score methodology. The outcome measures were the first and the total number of HHF, and mortality for heart failure or all causes.Results A total of 8288 matched pairs of patients were analyzed. During a median of 1.5 years, the first event of HHF occurred in 339 patients with sitagliptin and 275 patients never exposed to a DPP-4 inhibitor (hazard ratio: 1.21, 95% confidence interval: 1.04-1.42, P = 0.017); all-cause mortality was similar (hazard ratio: 0.87, 95% confidence interval: 0.74-1.03, P = 0.109). The risk for HHF was proportional to exposure (hazard ratio: 1.09, 95% confidence interval: 1.06-1.11, P < 0.001 for every 10% increase in adherence to sitagliptin). Overall, there were 935 events of HHF, in which the association between the number of HHF and the adherence to sitagliptin was linear. The greatest total number of HHF occurred in the patients with the highest adherence.Conclusions The use of sitagliptin was associated with a higher risk of HHF but no excessive risk for mortality was observed.",

keywords = "Sitagliptin Heart failure Outcome research",

author = "Wang, {Kang Ling} and Liu, {Chia Jen} and Chao, {Tze Fan} and Huang, {Chi Ming} and Wu, {Cheng Hsueh} and Chen, {Su Jung} and Yeh, {Chiu Mei} and Chen, {Tzeng Ji} and Lin, {Shing Jong} and Chiang, {Chern En}",

year = "2014",

month = nov,

day = "15",

doi = "10.1016/j.ijcard.2014.09.038",

language = "English",

volume = "177",

pages = "86--90",

journal = "International Journal of Cardiology",

issn = "0167-5273",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Sitagliptin and the risk of hospitalization for heart failure

T2 - A population-based study

AU - Wang, Kang Ling

AU - Liu, Chia Jen

AU - Chao, Tze Fan

AU - Huang, Chi Ming

AU - Wu, Cheng Hsueh

AU - Chen, Su Jung

AU - Yeh, Chiu Mei

AU - Chen, Tzeng Ji

AU - Lin, Shing Jong

AU - Chiang, Chern En

PY - 2014/11/15

Y1 - 2014/11/15

N2 - Background Saxagliptin was associated with an increased risk of hospitalization for heart failure (HHF) in diabetic patients with high cardiovascular risk. This study assessed the risk of HHF during an exposure to sitagliptin in general diabetic patients.Methods In Taiwan National Health Insurance research database, a study of the beneficiaries aged ≥ 45 years with diabetes treated with or without sitagliptin between March 2009 and July 2011 was conducted. Patients treated with sitagliptin were matched to patients never exposed to a dipeptidyl peptidase-4 (DPP-4) inhibitor by the propensity score methodology. The outcome measures were the first and the total number of HHF, and mortality for heart failure or all causes.Results A total of 8288 matched pairs of patients were analyzed. During a median of 1.5 years, the first event of HHF occurred in 339 patients with sitagliptin and 275 patients never exposed to a DPP-4 inhibitor (hazard ratio: 1.21, 95% confidence interval: 1.04-1.42, P = 0.017); all-cause mortality was similar (hazard ratio: 0.87, 95% confidence interval: 0.74-1.03, P = 0.109). The risk for HHF was proportional to exposure (hazard ratio: 1.09, 95% confidence interval: 1.06-1.11, P < 0.001 for every 10% increase in adherence to sitagliptin). Overall, there were 935 events of HHF, in which the association between the number of HHF and the adherence to sitagliptin was linear. The greatest total number of HHF occurred in the patients with the highest adherence.Conclusions The use of sitagliptin was associated with a higher risk of HHF but no excessive risk for mortality was observed.

AB - Background Saxagliptin was associated with an increased risk of hospitalization for heart failure (HHF) in diabetic patients with high cardiovascular risk. This study assessed the risk of HHF during an exposure to sitagliptin in general diabetic patients.Methods In Taiwan National Health Insurance research database, a study of the beneficiaries aged ≥ 45 years with diabetes treated with or without sitagliptin between March 2009 and July 2011 was conducted. Patients treated with sitagliptin were matched to patients never exposed to a dipeptidyl peptidase-4 (DPP-4) inhibitor by the propensity score methodology. The outcome measures were the first and the total number of HHF, and mortality for heart failure or all causes.Results A total of 8288 matched pairs of patients were analyzed. During a median of 1.5 years, the first event of HHF occurred in 339 patients with sitagliptin and 275 patients never exposed to a DPP-4 inhibitor (hazard ratio: 1.21, 95% confidence interval: 1.04-1.42, P = 0.017); all-cause mortality was similar (hazard ratio: 0.87, 95% confidence interval: 0.74-1.03, P = 0.109). The risk for HHF was proportional to exposure (hazard ratio: 1.09, 95% confidence interval: 1.06-1.11, P < 0.001 for every 10% increase in adherence to sitagliptin). Overall, there were 935 events of HHF, in which the association between the number of HHF and the adherence to sitagliptin was linear. The greatest total number of HHF occurred in the patients with the highest adherence.Conclusions The use of sitagliptin was associated with a higher risk of HHF but no excessive risk for mortality was observed.

KW - Sitagliptin Heart failure Outcome research

UR - http://www.scopus.com/inward/record.url?scp=84909956991&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2014.09.038

DO - 10.1016/j.ijcard.2014.09.038

M3 - Article

C2 - 25499347

AN - SCOPUS:84909956991

SN - 0167-5273

VL - 177

SP - 86

EP - 90

JO - International Journal of Cardiology

JF - International Journal of Cardiology

IS - 1

ER -

Sitagliptin and the risk of hospitalization for heart failure: A population-based study

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this